Shortening treatment of tuberculosis: lessons from fluoroquinolone trials

Affiliations

¹ Division of Medicine, University College London, London, UK.
² Division of Medicine, University College London, London, UK; Centre for Respiratory Medicine and Department of Medicine, Royal Free London NHS Foundation Trust, London, UK.
³ Medical Research Council Clinical Trials Unit, University College London, London, UK.
⁴ Division of Infection and Immunity, University College London, London, UK.
⁵ Medical Research Council Clinical Trials Unit, University College London, London, UK; Centre for Infectious Disease Epidemiology, Research Department of Infection and Population Health, University College London, London, UK. Electronic address: i.abubakar@ucl.ac.uk.

Camus Nimmo et al. Lancet Infect Dis. 2015 Feb.

. 2015 Feb;15(2):141-3.

doi: 10.1016/S1473-3099(14)70885-0. Epub 2015 Jan 19.

¹ Division of Medicine, University College London, London, UK.
² Division of Medicine, University College London, London, UK; Centre for Respiratory Medicine and Department of Medicine, Royal Free London NHS Foundation Trust, London, UK.
³ Medical Research Council Clinical Trials Unit, University College London, London, UK.
⁴ Division of Infection and Immunity, University College London, London, UK.
⁵ Medical Research Council Clinical Trials Unit, University College London, London, UK; Centre for Infectious Disease Epidemiology, Research Department of Infection and Population Health, University College London, London, UK. Electronic address: i.abubakar@ucl.ac.uk.

No abstract available

MeSH terms